Lipids & metabolic liver disease
Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials
Pooled result · TG reductionResult — go to the resultMD −63.26 95% CI −70.04 to −56.47Authors' conclusion
ApoC-III inhibitors significantly improved triglyceride levels and other lipid parameters and, most importantly, substantially reduced the risk of acute pancreatitis. Future trials are needed to evaluate their effects on cardiovascular outcomes.
Study context
- Population
- Patients with hypertriglyceridemia
- Participants
- 3,934 patients15 randomised controlled trials (RCTs)
- Comparison
- ApoC-III inhibitors vs placebo
- Outcome
- TG reduction
Methodological detailsfrequentist network meta-analysis
- Frequentist network meta-analysis
Pooled result
As reported in the abstract
MD
−63.26
95% CI −70.04 to −56.47
P < 0.01
Olezarsen 80 mg administered every 4 weeks
MD −63.26 (95% CI −70.04 to −56.47); P < 0.01
Every 4 weeks, as printed
Further pooled results
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Incidence of pancreatitis | 0.16 (0.07–0.33) | P < 0.01 | |
| 0.050.21520Hazard ratio (log scale) |
Safety
- None of the agents significantly increased the risk of serious adverse events
Original publication
Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 31 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →